A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This clinical trial is studying advanced solid tumors. Solid tumors are cancers that start in a part of your body like your lungs or liver instead of your blood. Once tumors have grown bigger in one place but haven't spread, they're called locally advanced. If your cancer has spread to other parts of your body, it's called metastatic. When a cancer has gotten so big it can't easily be removed or has spread to other parts of the body, it is called unresectable. These types of cancer are harder to treat. Participants in this study must have cancer that has come back or did not get better with treatment. Participants must have a solid tumor cancer that can't be treated with standard of care drugs. This clinical trial uses an experimental drug called PF-08046050. PF-08046050 is a type of antibody-drug conjugate or ADC. ADCs are designed to stick to cancer cells and kill them. They may also stick to some normal cells. This study will test the safety of PF-08046050 in participants with solid tumors that are hard to treat or have spread throughout the body. This study has 5 different study parts. Part A and Part B of the study will find out how much PF-08046050 should be given to participants. Part C will use the information from Parts A and B to see if PF-08046050 is safe and if it works to treat certain solid tumor cancers. Part D and E of the study, together with information from Parts A and B, will find out how much PF-08046050 should be given in combination with other anti-cancer agents. Part E will use the information from Parts A, B, and D to see if PF-08046050 is safe in combination with other anti-cancer agents and if it works to treat a certain solid tumor.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Pacjent ma zaawansowanego litego raka (np. płuca, jelita, żołądka, trzustki), który nie jest łatwy do usunięcia chirurgicznie lub rozprzestrzenił się w organizmie.
- •Rak u pacjenta powrócił lub nie poprawił się po wcześniejszym leczeniu.
- •Rak pacjenta nie reaguje na standardowe leki lub nie ma dla niego odpowiedniego standardowego leczenia.
- •Rak pacjenta musiał być potwierdzony badaniami laboratoryjnymi (nie wystarczy tylko stwierdzenie obecności guza).
- •W niektórych częściach badania pacjent musiał przejść ograniczoną liczbę wcześniejszych linii leczenia.
✗ Disqualifies
- •Pacjent ma nowotwór, który nie jest rakiem litym (np. białaczkę).
- •Pacjent ma guzy, które są łatwe do usunięcia chirurgicznie.
- •Rak pacjenta nie rozprzestrzenił się w organizmie i można go łatwo usunąć.
- •Pacjent miał bardzo wiele wcześniejszych prób leczenia nowotworu, które mogłyby wpłynąć na działanie badanego leku.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 22, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (48)
Mayo Clinic Hospital
Phoenix, United States
Mayo Clinic
Scottsdale, United States
City of Hope (City of Hope National Medical Center, City of Hope Medical Center)
Duarte, United States
IP Address: City of Hope Investigational Drug Services(IDS)
Duarte, United States
University of Colorado Hospital - Anschutz Cancer Pavilion (ACP)
Aurora, United States
University of Colorado Hospital
Aurora, United States
Florida Cancer Specialists
Orlando, United States
Sarah Cannon Research Institute at Florida Cancer Specialists
Orlando, United States
Sidney Kimmel Comprehensive Cancer at Johns Hopkins
Baltimore, United States
Beth Israel Deaconess Medical Center
Boston, United States
START Midwest
Grand Rapids, United States
Mayo Clinic Cancer Center
Rochester, United States
Mayo Clinic
Rochester, United States
MidAmerica Cancer Care
Kansas City, United States
Sarah Cannon Research Institute - Pharmacy
Nashville, United States
SCRI Oncology Partners
Nashville, United States
The University of Texas MD Anderson Cancer Center
Houston, United States
NEXT Dallas
Irving, United States
South Texas Accelerated Research Therapeutics, LLC
San Antonio, United States
START Mountain Region
Salt Lake City, United States
South Texas Accelerated Research Therapeutics Mountain Region
West Valley City, United States
The Ottawa Hospital
Ottawa, Canada
University Health Network
Toronto, Canada
University Health Network, Princess Margaret Cancer Centre
Toronto, Canada
McGill University Health Centre
Montreal, Canada
The Sixth Affiliated Hospital of Sun Yat-sen University
Guangzhou, China
Shandong First Medical University Cancer Hospital
Jinan, China
Fudan University Shanghai Cancer Center
Shanghai, China
Institut Gustave Roussy
Villejuif, France
Gustave Roussy
Villejuif, France
Hadassah Medical Organization
Jerusalem, Israel
National Cancer Center Hospital East
Kashiwa, Japan
Netherlands Cancer Institute
Amsterdam, Netherlands
Institut Catala d'Oncologia - Hospital Duran i Reynals (ICO L'Hospitalet)
L'Hospitalet de Llobregat, Spain
Ascires Cetir
Barcelona, Spain
Ascires CETIR
Esplugues de Llobregat, Spain
Servicio de Farmacia ICO - Planta 0
L'Hospitalet de Llobregat, Spain
Hospital Universitario HM Sanchinarro-CIOCC-START Madrid
Madrid, Spain
Karolinska University Hospital
Solna, Sweden
ApoEx NKS
Stockholm, Sweden
The Harley Street Clinic (THSC)
London, United Kingdom
Edinburgh Cancer Centre, Western General Hospital
Edinburgh, United Kingdom
Lothian Health Board
Edinburgh, United Kingdom
Western General Hospital
Edinburgh, United Kingdom
Sarah Cannon Research Institute UK
London, United Kingdom
Diagnostic Centre
London, United Kingdom
The Harley Street Clinic
London, United Kingdom
Radiology
London, United Kingdom
Trial contact
Pfizer CT.gov Call Center
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/7/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.